

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Omaveloxolone for treating Friedrich’s ataxia in people 16 years and over ID6423

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During draft scope consultation consultees highlighted that:

- there is variable access to the 3 treatment specialist centres
- some people travel long distances at considerable cost
- a negative NICE recommendation for omaveloxolone will lead to private use for those who can afford it, which discriminates against poorer, disadvantaged and vulnerable people who already lose out on supportive therapies.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

These do not constitute equalities issues that will need to be explicitly addressed by committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Associate Director (name):** Emily Crowe

**Date:** 06/10/2024